Curry P V, Rowland E, Krikler D M
Pacing Clin Electrophysiol. 1979 Mar;2(2):137-51. doi: 10.1111/j.1540-8159.1979.tb05193.x.
An automatic dual-demand pacemaker has been used in six patients to treat refractory attacks of paroxysmal re-entry atrioventricular tachycardia that occurred in the Wolff-Parkinson-White syndrome. The pacemaker was designed to pace at a fixed rate of 70 beats per minute when sensed heart rates were either below this rate or above 150 beats per minute; in the latter case, it would compete with the paroxysmal tachycardia and interrupt it after a short period of random scaning. The best location for the permanent pacing electrode and the feasibility of using the pacemaker were tested in each case during a detailed preliminary intracardiac electrophysiological study. The permanent pacing electrode was positioned in the coronary sinus in three patients and was attached to the epicardium of either the left or right ventricle in another three. All patients were given regular oral doses of verapamil or propranolol to enhance the effectiveness of the pacemaker system and, with the latter, to prevent pacemaker activation during sinus tachycardia. Over a follow-up period of between 11 and 47 months, the pacemaker system remained completely effective in three patients, but developed unreliable sensing in another two (one coronary sinus and one left ventricular lead). In the sixth patient the pacemaker was only effective when the rate of the tachycardia remained below 170 beats a minute, as when she was resting supine; when sitting or standing, however, her tachycardia rate considerably exceeded this value and the pacemaker was ineffective. Explantation of the pacemaker and either successful cryosurgical ablation of the accesory AV pathway or treatment with amiodarone was undertaken in the three patients in whom the pacemaker had failed.
一台自动双需求起搏器已用于6例患者,以治疗预激综合征中发生的阵发性折返性房室性心动过速的难治性发作。该起搏器设计为当感知到的心率低于每分钟70次或高于每分钟150次时,以固定的每分钟70次的频率起搏;在后一种情况下,它将与阵发性心动过速竞争,并在短时间随机扫描后中断它。在详细的初步心内电生理研究中,对每例患者测试了永久起搏电极的最佳位置以及使用该起搏器的可行性。3例患者的永久起搏电极置于冠状窦,另外3例则附着于左心室或右心室的心外膜。所有患者均定期口服维拉帕米或普萘洛尔,以增强起搏器系统的有效性,对于后者,可防止窦性心动过速期间起搏器激活。在11至47个月的随访期内,起搏器系统在3例患者中仍完全有效,但在另外2例(1例冠状窦导联和1例左心室导联)中出现了不可靠的感知。在第6例患者中,起搏器仅在心动过速速率保持在每分钟170次以下时有效,如她仰卧休息时;然而,当她坐着或站立时,她的心动过速速率大大超过这个值,起搏器无效。在起搏器失效的3例患者中,进行了起搏器植入以及成功的冷冻手术消融房室旁路或用胺碘酮治疗。